STOCK TITAN
  1. Home
  2. News
  3. HOOK

Hookipa Pharma Inc - HOOK STOCK NEWS

Welcome to our dedicated news page for Hookipa Pharma (Ticker: HOOK), a resource for investors and traders seeking the latest updates and insights on Hookipa Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Hookipa Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Hookipa Pharma's position in the market.

News
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
Rhea-AI Summary
HOOKIPA Pharma announced FDA clearance of its Investigational New Drug Application for HB-700, a novel arenaviral therapeutic vaccine for the treatment of KRAS-mutated cancers. The program targets five prevalent KRAS mutations in lung, colorectal, pancreatic, and other cancers, potentially benefiting more patients than single mutation inhibitors. The IND submission resulted in a $10 million milestone payment from Roche, giving HOOKIPA full control of the intellectual property portfolio and collaboration rights for the HB-700 program. Preclinical data will be presented at the ASCO 2024 Annual Meeting, showcasing the company's commitment to advancing oncology treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
HOOKIPA Pharma Inc. grants 250,000 non-statutory options to its Chief Development Officer, Mark Winderlich, under the 2023 Inducement Plan. The options have an exercise price of $0.76 per share, a ten-year term, and vest over four years. This award was granted as an inducement material to Winderlich's acceptance of employment with HOOKIPA in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
Rhea-AI Summary
HOOKIPA announces alignment with FDA on pivotal trial design and protocol for HB-200 in combination with pembrolizumab, receiving PRIME designation from EMA. Investor call scheduled to discuss regulatory interactions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
conferences
News
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Rhea-AI Summary
HOOKIPA Pharma Inc. reports promising Phase 2 data for HB-200 in combination with pembrolizumab for head and neck cancers. They are finalizing IND activities for HB-700 and progressing on infectious disease programs. Financially, they have a strong cash position of $117.5 million at year end 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
earnings
-
News
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
Rhea-AI Summary
HOOKIPA Pharma Inc. (HOOK) CFO to present at Leerink Partners Global Biopharma Conference 2024. The company focuses on immunotherapeutics using its proprietary arenavirus platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
conferences
-
News
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
Rhea-AI Summary
HOOKIPA Pharma Inc. announced strategic priorities to focus on advancing clinical programs for HPV16+ head and neck cancers and Gilead-partnered infectious disease programs. The company will prioritize the clinical development of a randomized trial for HB-200 in HPV16+ head and neck squamous cell carcinoma, implement cost-saving initiatives, and reduce its workforce by 30 percent. HOOKIPA will also regain global development rights to HB-700 program for KRAS-mutated cancers from Roche and maintain a strong cash position of $117.5 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.13%
Tags
partnership
News
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
Rhea-AI Summary
HOOKIPA Pharma Inc. appoints Mark Winderlich, PhD, as Chief Development Officer, effective April 1, 2024. Dr. Winderlich brings extensive experience in leading drug development processes and will focus on advancing the HB-200 program to improve the standard of care for people with advanced HPV16+ head and neck cancer. He joins HOOKIPA from Evotec SE, where he led the partnership with Bristol Myers Squibb in oncology and played key roles in the development of multiple drug candidates. Dr. Winderlich's appointment reflects HOOKIPA's commitment to advancing novel arenaviral therapies for cancer and infectious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.15%
Tags
management clinical trial
-
News
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
Rhea-AI Summary
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced that Gilead Sciences has purchased 15 million shares of HOOKIPA’s common stock for approximately $21.25 million, at a price of $1.4167 per share. Following the transaction, Gilead holds 19.4% of HOOKIPA’s outstanding shares of common stock. The equity investment aims to advance the Gilead-partnered HIV therapeutic program through Phase 1, with the trial expected to commence in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
52.74%
Tags
none
-
News
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus
Rhea-AI Summary
HOOKIPA Pharma Inc. (NASDAQ: HOOK) has received FDA clearance for its Investigational New Drug (IND) application for HB-500, a novel arenaviral therapeutic vaccine for the treatment of HIV. The Phase 1 trial will commence in the first half of 2024, following the publication of peer-reviewed preclinical data in Nature Partner Journals (NPJ) Vaccines. The vaccine has shown safety, immunogenicity, and efficacy in preclinical testing, and Gilead Sciences, Inc. has the exclusive right to assume further development of the program after HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
clinical trial
News
HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Rhea-AI Summary
HOOKIPA Pharma Inc. (NASDAQ: HOOK) reported positive preliminary Phase 2 data for HB-200 in combination with pembrolizumab in the 1st-line setting for advanced HPV16+ head and neck cancer. The data reinforce strong objective response rate and disease control rate reported in Q2 2023. The company also published peer-reviewed preclinical data for HB-400 program in The Journal of Infectious Disease. Recruitment is ongoing for two Phase 1 clinical trials for advanced prostate cancer and chronic hepatitis B. IND-enabling activities are in progress to advance two additional therapeutic candidates into the clinic in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12%
Tags
earnings
Stock HOOK logo
Hookipa Pharma Inc

Nasdaq:HOOK

HOOK Rankings

#4405 Ranked by Market Cap
#5063 Ranked by Stock Gains
N/A Ranked by Dividends

HOOK Stock Data

77.82M
58.31M
19.59%
39.38%
0.32%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
New York

About HOOK

hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and cd8+ t cells. both, vaxwave® and therat®, can be administered repeatedly while maintaining their efficacy. therat® induced cd8+ t cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive t cell therapy. hookipa’s “off-the shelf” viral vectors are administered systemically. they target dendritic cells in vivo and activate the immune system. in immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). at hookipa we have successfully completed a phase 1 trial of a